Navigation Links
New Class of Drugs Might Treat Many Conditions
Date:5/9/2008

Vaptans ease painful periods, glaucoma, depression and many other diseases, researchers say

FRIDAY, May 9 (HealthDay News) -- A new class of drugs called vaptans may be able to treat a wide variety of conditions including painful periods, brain hemorrhage, psychotic disorders and glaucoma, Belgian researchers report.

Vaptans, short for vasopressin-receptor antagonists, work by targeting the vasopressin hormone system, which plays an important role in controlling blood and water volume in the body. These drugs, which can be taken orally or intravenously, block the action of vasopressin, according to the report in the May 10 issue of The Lancet.

In the report, Dr. Guy Decaux, from Erasmus University Hospital in Brussels, and his colleagues reviewed the current state of vaptans, of which there are several subclasses, that have been development or are under development.

Among these new drugs are relcovaptan, which has shown initial positive results in treating painful periods, as well as Raynaud's disease, which affects blood flow to the arms and legs, and tocolysis, (premature labor, leading to premature birth).

Another subclass of vaptans that include mozavaptan, lixivaptan, satavaptan and tolvaptan are diuretics, which remove water from the body, while maintaining the body's electrolyte, or salt mineral, balance. Other diuretics don't maintain the body's electrolyte balance, the researchers noted.

Some vaptans can be used to treat hyponatremia, which is a life-threatening loss of salt. Currently, conivaptan is the only vaptan approved by the U.S. Food and Drug Administration for treating hyponatremia.

Other vaptans in development might be used to treat kidney failure, diabetic nephropathy, a progressive kidney disease associated with diabetes, cirrhosis and depression, the researchers wrote.

In addition, early studies of vaptans for treating glaucoma, Menire's disease-- an inner ear condition affecting hearing and balance -- brain hemorrhage, and small-cell lung cancer, have had promising results, Decaux's team noted.

Despite these promising results, one expert isn't ready to called vaptans a miracle cure yet.

"This is nice review of an emerging class of drugs," said Dr. Gary S. Francis, director of the coronary intensive care unit at the Cleveland Clinic. "But it is a little early to know if they will prove to be highly useful."

More information

For more on conivaptan, visit the U.S. Food and Drug Administration.



SOURCES: Gary S. Francis, M.D., director, coronary intensive care unit, Cleveland Clinic; May 10, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
2. ADDA Kicks Off AD/HD Awareness Campaign with Four Regional Conferences Beginning Sept. 29 and Series of Fall Teleclasses
3. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
4. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
5. Theater Classes Help Docs Bedside Manners
6. Tarpinian: Misclassification is Theft
7. New class of RNA molecules may be important in human cancer
8. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
9. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
10. SATELLITE BROADCAST: Consumer Group Says Hillary Clintons Mandatory Health Insurance Plan is an Act of War on the Middle Class that Cant Afford $12k Policy
11. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Class of Drugs Might Treat Many Conditions
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, cloud-based ... named the best Sales Team of 2016 as part of the 2016 SIIA ... the Software & Information Industry Association (SIIA), the principal trade association for the ...
(Date:11/30/2016)... ... 2016 , ... "I hate when the mixture of saliva and toothpaste runs ... inventor from Bridgewater, N.J. "I thought that there had to be a way to ... the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... British Columbia , December 2, 2016 - bioLytical lanza ... las nuevas directrices de la OMS     Continue Reading ... ... , , ... de enfermedades infecciosas, ha anunciado hoy que está expandiendo el lanzamiento de su ...
(Date:12/2/2016)... , December 2, 2016 Persistence ... pacemaker market in its upcoming report titled, "Global Market Study on ... Declining CAGR of -1.4% between 2016 and 2024". The global ... in 2015 and this is likely to decline to ... the global cardiac pacemaker market is anticipated to exhibit ...
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary device ... in the Emergency Response Training and Support Services (ERTSS) ... to have LifeVac become part of the ERTSS mission ... and CEO of LifeVac. "Having an established network of ... effectively will help leverage our efforts to spread LifeVac,s ...
Breaking Medicine Technology: